Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 12/20 | 0.45 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30445234 | 1.00 | GRM5 (0.45) | GRM5IRAK4USP30JAK2JAK1 | |
| SCHEMBL24135253 | 0.87 | GRM5 (0.46) | GRM5IRAK4USP30JAK2JAK1 | |
| SCHEMBL30445068 | 0.81 | MTOR (0.35) | MTOREGLN1 | |
| SCHEMBL20168528 | 0.81 | MTOR (0.35) | MTOREGLN1 | |
| SCHEMBL17966629 | 0.80 | KDM4E (0.45) | GRM5PANK3EGLN1 | |
| SCHEMBL30444946 | 0.80 | KDM4E (0.45) | GRM5PANK3EGLN1 | |
| SCHEMBL18585844 | 0.78 | ALDH1A1 (0.48) | IRAK4MTOREGLN1 | |
| SCHEMBL31398745 | 0.76 | GRM5 (0.54) | GRM5IRAK4MTOR | |
| SCHEMBL22606709 | 0.76 | EGLN1 (0.44) | GRM5IRAK4PANK3EGLN1 | |
| SCHEMBL1931670 | 0.75 | CYP11B1 (0.41) | GRM5MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327390-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2024-10-03 | — | — | US | disclosed |
| EP-3929194-B1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-17 | — | — | EP | disclosed |
| US-RE49700-E1 | Substituted nitrogen containing compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-RE49700-E1 | Substituted nitrogen containing compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-RE49700-E1 | Substituted nitrogen containing compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| CN-110678463-B | Substituted nitrogen-containing compounds | 百时美施贵宝公司 | 2023-06-06 | — | — | CN | disclosed |
| US-20230124468-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-04-20 | — | — | US | disclosed |
| EP-3929194-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | Bristol-Myers Squibb Company (US) | 2021-12-29 | — | — | EP | disclosed |
| EP-3929194-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | Bristol-Myers Squibb Company (US) | 2021-12-29 | — | — | EP | disclosed |
| EP-3630752-B1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-30 | — | — | EP | disclosed |
| US-20200339550-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-29 | — | — | US | disclosed |
| US-20200109135-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-04-09 | — | — | US | disclosed |
| US-20200109135-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-04-09 | — | — | US | disclosed |
| EP-3630752-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | Bristol-Myers Squibb Company (US) | 2020-04-08 | — | — | EP | disclosed |
| US-20180346453-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2018-12-06 | — | — | US | disclosed |
| WO-2018222795-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230124468-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | NR0B1, GRK1, GRIN1 | GRM5 689/4885IRAK4 806/4885USP30 4665/4885 |
| US-20240327390-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | NR0B1, GRK1, GRIN1 | GRM5 689/4885IRAK4 806/4885USP30 4665/4885 |
| US-20180346453-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | NR0B1, GRK1, GRIN1 | GRM5 689/4885IRAK4 806/4885USP30 4665/4885 |
| US-20200109135-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | NR0B1, GRK1, GRIN1 | GRM5 689/4885IRAK4 806/4885USP30 4665/4885 |
| US-20200339550-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | NR0B1, GRK1, GRIN1 | GRM5 689/4885IRAK4 806/4885USP30 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.